Phenasen 10 mg/10 ml Concentrated solution for infusion)
PDF Leaflet Revision Date: 06 February 2023
Clinical Summary
Quick overview from the medicine insert
Indication
Induction and consolidation treatment for acute promyelocytic leukaemia.
Dosage (summary)
0.15 mg/kg/day IV until hematological CR or max 60 days; consolidation 0.15 mg/kg/day 5 days/week.
Special Populations
- Elderly
- Renal impairment
- Hepatic impairment
Pregnancy & Breastfeeding
Embryotoxic and teratogenic; contraindicated in pregnancy and breastfeeding.
Key Drug Interactions
- QT prolonging medications
- Hepatotoxic medications
Contraindications
- Hypersensitivity to arsenic trioxide
- Heart block
- Congestive cardiac failure
Common side effects
- Leukocytosis
- Hepatotoxicity
- Peripheral neuropathy
- QT prolongation
Counselling Points
- Monitor for signs of APL differentiation syndrome
- Use effective contraception
- Avoid QT prolonging drugs
Serious warnings
- APL differentiation syndrome
- Risk of torsade de pointes
- Potential for sudden death
Important Disclaimer
The Phenasen 10 mg/10 ml Concentrated solution for infusion) professional information leaflet below is the property of Key Oncologics and is provided on Medinsert exactly as issued, with no.. alterations or editorial changes. We make every effort to keep content current by updating documents as soon as new versions become available. Medinsert serves as a trusted access point for healthcare professionals, but does not replace official sources or clinical judgement. For more details, please read our full disclaimer. read more>>
Healthcare Professionals Only
This content is for registered healthcare professionals
Sign in or create a free account to read the full package insert.
Free for HPCSA-registered professionals. Powered by Medinsert.
